![]() "These new data show that, for some adult smokers who had previously taken CHANTIX but either did not quit smoking or relapsed after quitting, another quit attempt with CHANTIX may be fruitful." Romano, M.D., senior vice president and medicines development group head, Primary Care Business Unit, Pfizer Inc. The availability of pharmacological treatments has led to a large and growing population of smokers who have made previous quit attempts but were ultimately unsuccessful," said Steven J. "Smoking is considered a chronic, relapsing medical condition. The most commonly reported treatment-emergent adverse events were nausea, abnormal dreams and headache, with incidence rates similar to previous CHANTIX studies. The safety and tolerability profile of CHANTIX in this study was also consistent with previous studies. The efficacy rates were consistent with findings seen in other CHANTIX clinical trials in smokers who had not been previously treated with CHANTIX. ( NYS: PFE) announced today that a post-marketing study assessing the efficacy and safety of varenicline (CHANTIX ®/CHAMPIX ®) in a population of smokers who had made a previous attempt to quit smoking with CHANTIX, and either did not succeed in quitting or relapsed after treatment, met its primary endpoint.ĬHANTIX significantly increased continuous abstinence rates compared to placebo at weeks nine to 12, the last four weeks of treatment (primary endpoint). New Positive Top-line Results in Adult Smokers Re-treated With CHANTIX CHANTIX ® (varenicline) Demonstrates Efficacy in Smokers Who Previously Attempted to Quit Smoking with CHANTIX
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |